应用精准医学应对哮喘发作的异质性
本文综述哮喘发作在临床、病因和治疗维度的异质性,指出基于症状和严重程度分层的口服糖皮质激素(OCS)统一治疗已沿用70年。血嗜酸性粒细胞、呼出气一氧化氮(Feno)和病原微生物快速检测等生物标志物可优化评估,生物标志物指导的管理有望减少OCS和抗生素使用并改善结局。
要点
- 哮喘发作具有临床、病因和治疗维度的异质性,统一OCS治疗可能并非最优。
- 血嗜酸性粒细胞、Feno和微生物检测有助于细化哮喘发作的评估。
- 生物标志物指导的管理可能减少OCS和抗生素使用,改善患者结局。
核心结论
- 哮喘发作是病因、内型和表型多样的复杂事件,新兴证据支持将生物标志物纳入临床评估以优化管理。
- 认识哮喘异质性可推动诊疗向精准医学转变,减少对OCS的依赖并改善患者结局。
研究设计与样本
- 综述性文章,汇总近期关于哮喘发作异质性的临床、病因和治疗维度研究。
主要发现
- 近期研究凸显哮喘发作在临床、病因和治疗维度的异质性。
- 使用血嗜酸性粒细胞、Feno和即时病原微生物分子检测的生物标志物评估改善了发作评价。
- 观察性研究和试验探索了生物标志物指导的管理以减少OCS和抗生素使用,可能改善结局。
- 在接受生物制剂的患者中识别出不同的炎症和OCS反应特征,强调发作的复杂性及残余2型炎症通路的重要性。
- 气道微生物组研究显示微生物失调与临床和炎症聚类相关。
关键数值与推荐
- 严重哮喘发作定义为哮喘恶化需要口服糖皮质激素(OCS)治疗至少48小时未缓解症状、肺功能下降或两者兼有。
临床怎么用
- 在哮喘发作评估中可考虑纳入血嗜酸性粒细胞、Feno和微生物检测等生物标志物以细化管理。
- 基于生物标志物的分层管理可能有助于减少OCS和抗生素的不必要使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC IMPORTANCE: The standard of care for management of asthma attacks has remained unchanged for 70 years, relying on a symptom-based, severity-stratified approach. Severe asthma attacks are defined by a worsening of asthma requiring oral corticosteroid (OCS) treatment for unresolved symptoms for at least 48 hours, decreased lung function, or both. The 1-size-fits-all strategy with OCS treatment overlooks the biological mechanisms driving attacks and may lead to suboptimal outcomes. Importantly, OCS-related toxicities lead to significant morbidity, and cumulative OCS use has been associated with increased mortality. Antibiotics, often used indiscriminately, also increase adverse events and antimicrobial resistance. REVIEW FINDINGS: Recent studies have highlighted the heterogeneity of asthma attacks across clinical, etiologic, and therapeutic dimensions. Biomarker-informed assessments using blood eosinophils, exhaled nitric oxide (Feno), and point-of-care microbial molecular testing have improved the evaluation of attacks. Observational studies and trials have explored biomarker-guided management to reduce OCS and antibiotic use, potentially improving outcomes. Distinct inflammatory and OCS response profiles were identified in patients receiving biologics, emphasizing the complexity of attacks and the importance of residual (untreated) type 2 inflammatory pathways. Studies of the airway microbiome revealed that microbial dysbiosis is associated with clinical and inflammatory clusters. SUMMARY: Asthma attacks are complex episodes with diverse causes, endotypes, and phenotypes. Emerging evidence supports incorporating biomarkers (blood eosinophils, Feno, and microbial testing) into clinical assessment to refine management. Recent evidence expands our understanding of exacerbation mechanisms, highlighting the need for tailored management strategies. Recognizing asthma heterogeneity could shift care toward precision medicine, reducing OCS reliance and improving patient outcomes.
引用
- Celis-Preciado, Ben Hamou-Kuijpers, Ramakrishnan, et al. Applying Precision Medicine to the Heterogeneity of Asthma Attacks. Chest. 2025. PMID: 41241145. doi:10.1016/j.chest.2025.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。